TrialJournal of Alzheimer's disease : JAD2025
Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study.
Wiesław J Cubała et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.